Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Inventory (2019 - 2025)

Burning Rock Biotech has reported Inventory over the past 7 years, most recently at $6.8 million for Q4 2025.

  • For Q4 2025, Inventory fell 8.49% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $6.8 million, down 8.49%, while the annual FY2025 figure was $6.9 million, 19.04% down from the prior year.
  • Inventory for Q4 2025 was $6.8 million at Burning Rock Biotech, down from $7.7 million in the prior quarter.
  • Over five years, Inventory peaked at $21.1 million in Q3 2022 and troughed at $6.8 million in Q4 2025.
  • A 5-year average of $13.4 million and a median of $12.9 million in 2023 define the central range for Inventory.
  • Biggest five-year swings in Inventory: skyrocketed 87.76% in 2021 and later plummeted 47.69% in 2023.
  • Year by year, Inventory stood at $19.3 million in 2021, then dropped by 4.92% to $18.3 million in 2022, then crashed by 47.69% to $9.6 million in 2023, then dropped by 21.92% to $7.5 million in 2024, then decreased by 8.49% to $6.8 million in 2025.
  • Business Quant data shows Inventory for BNR at $6.8 million in Q4 2025, $7.7 million in Q3 2025, and $8.1 million in Q2 2025.